Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study

Rinzivillo, Maria; Fazio, Nicola; Pusceddu, Sara; Spallanzani, Andrea; Ibrahim, Toni; Campana, Davide; Marconicini, Riccardo; Partelli, Stefano; Badalamenti, Giuseppe; Brizzi, Maria Pia; Catena, Laura; Schinzari, Giovanni; Carnaghi, Carlo; Berardi, Rossana; Faggiano, Antongiulio; Antonuzzo, Lorenzo; Spada, Francesca; Gritti, Sara; Femia, Daniela; Gelsomino, Fabio; Bongiovanni, Alberto; Ricci, Sergio; Brighi, Nicole; Falconi, Massimo; Fave, Gianfranco Delle; Panzuto, Francesco

doi:10.1016/j.pan.2018.01.005

Cited by 19 publications

(15 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A further two recently‐published retrospective studies, one from Italy and another from China, found similar efficacy of sunitinib in well‐differentiated pNET (Table ). The majority of the pNET were G2.…”

Section: Targeted Therapymentioning

confidence: 74%

Systemic treatment of pancreatic neuroendocrine tumors

Chan¹,

Chan

2019

Surgical Practice

View full text Add to dashboard Cite

Pancreatic neuroendocrine tumours (pNET) are a group of heterogeneous tumours. Despite being rare, their incidence is rising. While localized lesions can be cured with surgical resection, most patients present with metastatic disease. Systemic therapy is thus integral for the management of this rare entity. Numerous advancements have been made in the past decade in the systemic treatment of unresectable, metastatic pNET. Treatment options for pNET include somatostatin analogues, cytotoxic chemotherapy, targeted agents and peptide receptor radionuclide therapy. In this Review, we present the latest evidence for these treatment options.

show abstract

Section: Targeted Therapymentioning

confidence: 74%

Systemic treatment of pancreatic neuroendocrine tumors

Chan¹,

Chan

2019

Surgical Practice

View full text Add to dashboard Cite

show abstract

“…Sunitinib and everolimus have been approved for treatment of PanNETs for many years now due to the results from the performed studies. Collected data regarding the use of both targeted agents in real world setting confirm their benefit with similar PFS and even higher RR on average in the phase IV and retrospective studies [10,[65][66][67][68][69] as you may see on Table S2. Everyday practice shows that although active, sunitinib and everolimus are derive on significant toxicity and grade 3/4 side effects for patients (Table S2).…”

Section: Evidence Supporting the Use Of Targeted Therapiesmentioning

confidence: 95%

Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)

Megdanova-Chipeva

Lamarca

Backen

et al. 2020

Cancers

View full text Add to dashboard Cite

Pancreatic neuroendocrine tumours (PanNETs) are rare diseases and a good example of how research is not only feasible, but also of crucial importance in the scenario of rare tumours. Many clinical trials have been performed over the past two decades expanding therapeutic options for patients with advanced PanNETs. Adequate management relies on optimal selection of treatment, which may be challenging for clinicians due to the fact that multiple options of therapy are currently available. A number of therapies already exist, which are supported by data from phase III studies, including somatostatin analogues and targeted therapies (sunitinib and everolimus). In addition, chemotherapy remains an option, with temozolomide and capecitabine being one of the most popular doublets to use. Peptide receptor radionuclide therapy was successfully implemented in patients with well-differentiated gastro-entero-pancreatic neuroendocrine tumours, but with certain questions waiting to be solved for the management of PanNETs. Finally, the role of immunotherapy is still poorly understood. In this review, the data supporting current systemic treatment options for locally advanced or metastatic PanNETs are summarized. Strategies for treatment selection in patients with PanNETs based on patient, disease, or drug characteristics is provided, as well as a summary of current evidence on prognostic and predictive biomarkers. Future perspectives are discussed, focusing on current and forthcoming challenges and unmet needs of patients with these rare tumours.

show abstract

“…В 2018 г. Raymond и соавт. [6,7] подтвердили результаты 3 фазы в исследовании 4 фазы у пациентов с прогрессирующими неоперабельными НЭО ПЖ G1-2. Медиана ВБП у пациентов, получавших сунитиниб в дозе 37,5 мг в день ежедневно, составила 13,2 месяца, а частота объективных ответов -24,5%.…”

Section: Clinical Observationunclassified

Sunitinib in pancreatic neuroendocrine tumors. Clinical case

Маркович

Дронова

et al. 2019

Medicinskij sovet

View full text Add to dashboard Cite

1 Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина; 115478, Россия, Москва, Каширское шоссе, д. 24 2 Московский государственный медико-стоматологический университет имени А.И. Евдокимова; 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1 Резюме Представлено описание редкого клинического случая. У пациента 33 лет с нейроэндокринной опухолью (НЭО) G2 поджелудочной железы выявлено прогрессирование заболевания через 1,5 месяца после оперативного лечения в виде множественных метастазов в печень, лимфатические узлы гепатодуоденальной связки и забрюшинного пространства. Назначена таргетная терапия пероральным ингибитором протеинкиназ сунитинибом в дозировке 37,5 мг ежедневно и биотерапия препаратом из группы аналогов соматостатина ланреотидом, который используется в виде ежемесячных подкожных инъекций. После 12 месяцев лечения зафиксирован частичный эффект в виде уменьшения всех ранее выявленных метастатических очагов. После 17 месяцев совместного применения двух препаратов зафиксирован полный лечебный эффект по данным магнитно-резонансной терапии (МРТ). На настоящий момент пациент продолжает лечение в течение 25 месяцев. Полная регрессия метастатических очагов сохраняется в течение 8 месяцев. Показана возможность повышения противоопухолевой эффективности при использовании комбинации таргетной терапии и аналогов соматостатина. Совместное применение сунитиниба и ланреотида имеет выраженный противоопухолевый эффект в первой линии лекарственной терапии для высокодифференцированных НЭО поджелудочной железы и переносится без значимой токсичности. При длительном лечении удобство применения и доступность необходимой дозировки перорального препарата Сунитиниб-Натив и готовой инъекционной формы в виде депо позволяют сохранять привычный образ жизни, профессиональную деятельность и существенно не влияют на качество жизни пациентов. Необходимо продолжение исследования данной схемы лекарственной терапии первой линии для НЭО поджелудочной железы в рамках клинических протоколов. Ключевые слова: нейроэндокринная опухоль, рецепторы соматостатина, сунитиниб, таргетная терапия, ланреотид Для цитирования: Маркович А.А., Кузнецова А.А., Дронова Е.Л., Емельянова Г.С. Сунитиниб при нейроэндокринных опухолях поджелудочной железы. Клинический случай. AbstractThe article describes a rare clinical case. Progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal region was detected in a 33-year-old patient with G2 pancreatic neuroendocrine tumour (NET) 1.5 months after surgical treatment. The patient received targeted therapy with sunitinib, oral protein kinase inhibitor, at daily dose of 37.5 mg and biotherapy with lanreotide, an analogue of somatostatin, which is used as a monthly subcutaneous injection. A partial effect in the form of reduction of all previously identified metastatic foci was reported after 12 months of treatment. Magnetic resonance imaging (MRI) showed a full therapeutic effect after 17 months of co-use of two drug...

show abstract

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study

Abstract: The present real-world experience shows that sunitinib is a safe and effective treatment for panNETs, even in the clinical setting of heavily pre-treated, progressive diseases.

Cited by 19 publications

References 24 publications

Systemic treatment of pancreatic neuroendocrine tumors

Systemic treatment of pancreatic neuroendocrine tumors

Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)

Sunitinib in pancreatic neuroendocrine tumors. Clinical case

Contact Info

Product

Resources

About